These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 31486755)

  • 1. KRAS: A Promising Therapeutic Target for Cancer Treatment.
    Wu HZ; Xiao JQ; Xiao SS; Cheng Y
    Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Mutant KRAS for Anticancer Therapy.
    Chen F; Alphonse MP; Liu Y; Liu Q
    Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Discovery by Targeting Mutant KRAS.
    Ye N
    Curr Top Med Chem; 2019; 19(23):2079-2080. PubMed ID: 31762422
    [No Abstract]   [Full Text] [Related]  

  • 4. Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.
    Pandey D; Chauhan SC; Kashyap VK; Roy KK
    Eur J Med Chem; 2024 Nov; 277():116771. PubMed ID: 39167893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting mutated GTPase KRAS in tumor therapies.
    Fan G; Lou L; Song Z; Zhang X; Xiong XF
    Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges.
    Shao YT; Ma L; Zhang TH; Xu TR; Ye YC; Liu Y
    Curr Top Med Chem; 2019; 19(23):2143-2157. PubMed ID: 31456522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic Lethal Vulnerabilities in
    Aguirre AJ; Hahn WC
    Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29101114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS as a Therapeutic Target.
    McCormick F
    Clin Cancer Res; 2015 Apr; 21(8):1797-801. PubMed ID: 25878360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.
    Porru M; Pompili L; Caruso C; Biroccio A; Leonetti C
    J Exp Clin Cancer Res; 2018 Mar; 37(1):57. PubMed ID: 29534749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Kras
    Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
    J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.
    Tripathi P; Kumari R; Pathak R
    Int Rev Cell Mol Biol; 2024; 385():1-39. PubMed ID: 38663957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
    Holderfield M; Lee BJ; Jiang J; Tomlinson A; Seamon KJ; Mira A; Patrucco E; Goodhart G; Dilly J; Gindin Y; Dinglasan N; Wang Y; Lai LP; Cai S; Jiang L; Nasholm N; Shifrin N; Blaj C; Shah H; Evans JW; Montazer N; Lai O; Shi J; Ahler E; Quintana E; Chang S; Salvador A; Marquez A; Cregg J; Liu Y; Milin A; Chen A; Ziv TB; Parsons D; Knox JE; Klomp JE; Roth J; Rees M; Ronan M; Cuevas-Navarro A; Hu F; Lito P; Santamaria D; Aguirre AJ; Waters AM; Der CJ; Ambrogio C; Wang Z; Gill AL; Koltun ES; Smith JAM; Wildes D; Singh M
    Nature; 2024 May; 629(8013):919-926. PubMed ID: 38589574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers.
    He H; Xu C; Cheng Z; Qian X; Zheng L
    Curr Top Med Chem; 2019; 19(23):2128-2142. PubMed ID: 31475900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting cancer with small-molecule pan-KRAS degraders.
    Popow J; Farnaby W; Gollner A; Kofink C; Fischer G; Wurm M; Zollman D; Wijaya A; Mischerikow N; Hasenoehrl C; Prokofeva P; Arnhof H; Arce-Solano S; Bell S; Boeck G; Diers E; Frost AB; Goodwin-Tindall J; Karolyi-Oezguer J; Khan S; Klawatsch T; Koegl M; Kousek R; Kratochvil B; Kropatsch K; Lauber AA; McLennan R; Olt S; Peter D; Petermann O; Roessler V; Stolt-Bergner P; Strack P; Strauss E; Trainor N; Vetma V; Whitworth C; Zhong S; Quant J; Weinstabl H; Kuster B; Ettmayer P; Ciulli A
    Science; 2024 Sep; 385(6715):1338-1347. PubMed ID: 39298590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
    Korzeniecki C; Priefer R
    Eur J Med Chem; 2021 Feb; 211():113006. PubMed ID: 33228976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS Alleles: The Devil Is in the Detail.
    Haigis KM
    Trends Cancer; 2017 Oct; 3(10):686-697. PubMed ID: 28958387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutics Targeting Mutant KRAS.
    Thein KZ; Biter AB; Hong DS
    Annu Rev Med; 2021 Jan; 72():349-364. PubMed ID: 33138715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS mutation: from undruggable to druggable in cancer.
    Huang L; Guo Z; Wang F; Fu L
    Signal Transduct Target Ther; 2021 Nov; 6(1):386. PubMed ID: 34776511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS: From undruggable to a druggable Cancer Target.
    Uprety D; Adjei AA
    Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ras and exosome signaling.
    Sexton RE; Mpilla G; Kim S; Philip PA; Azmi AS
    Semin Cancer Biol; 2019 Feb; 54():131-137. PubMed ID: 30769101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.